ANGLE has announced the presentation of new Parsortix system data from a proof-of-concept study in patients with the aggressive brain cancer glioblastoma (GBM) at the 7th Advances in Circulating Tumour Cells (ACTC) meeting. The poster presentation reported data from 15 newly diagnosed, treatment-naïve (no prior treatment) GBM patients whose blood was processed using the Parsortix system. The key findings from the study were: (i) CTCs were found in 60% of patients, with clusters, known to carry h ....
